Wegovy or Ozempic: Which Is Better, and Why Aren’t They the Same?

Ozempic and Wegovy both contain semaglutide, are manufactured by Novo Nordisk, and are administered as once-weekly subcutaneous injections. Despite sharing the same active ingredient, they are not the same medication.

Understanding Ozempic vs. Wegovy starts with one critical distinction: Ozempic was approved by the FDA for type 2 diabetes management in 2017, while Wegovy was approved in 2021 specifically for weight management. Recognizing these approval dates helps you understand their clinical roles and how they may fit your health goals.

This guide breaks down the exact differences, the clinical evidence supporting each, and how to determine which option best fits your health goals.

Why Ozempic and Wegovy Are Not the Same Medication

Both medications use semaglutide as their active ingredient. Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist that mimics a natural hormone produced in the gut after eating. It slows gastric emptying, reduces appetite, and stimulates insulin secretion in a glucose-dependent manner.

The difference lies in how the FDA classified and approved each drug. Ozempic received FDA approval in December 2017 specifically for improving glycemic control in adults with type 2 diabetes. It also carries approvals for reducing cardiovascular risk in diabetic patients with heart disease and for slowing kidney disease progression in patients with type 2 diabetes and chronic kidney disease.

Wegovy received separate FDA approval in June 2021 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. In March 2024, the FDA expanded Wegovy’s approval to include cardiovascular risk reduction in adults with obesity or overweight and established heart disease.

The higher Wegovy dose of 2.4 mg weekly can lead to greater weight loss, helping you feel more in control of your weight management goals.

Ozempic vs Wegovy: Head-to-Head Comparison

The following table outlines the key differences between Ozempic and Wegovy across the major categories that patients and providers consider when choosing between them.

What the Clinical Trials Show About Weight Loss

The weight loss data for these two medications come from separate clinical trial programs. Ozempic was studied in the SUSTAIN trials, which focused on blood sugar reduction in patients with type 2 diabetes. Wegovy was studied in the STEP trials, which specifically measured weight loss outcomes.

In the STEP 1 trial published in the New England Journal of Medicine, adults with overweight or obesity (without diabetes) who received semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks. That same trial showed that 86% of participants achieved at least 5% weight loss, and about one third lost 15% or more of their starting weight.

By comparison, patients using Ozempic at 1 mg in the SUSTAIN 1 trial lost approximately 7.7 pounds more than placebo over 30 weeks. This weight loss occurred as a secondary benefit while the primary goal was to improve HbA1c.

The difference in weight-loss outcomes directly relates to the dose. Wegovy’s 2.4 mg maintenance dose is 20% higher than Ozempic’s maximum dose of 2 mg, and the STEP trials enrolled patients specifically for weight management.

Side Effects: Are They Different?

Both medications share the same side effect profile because they contain the same active ingredient. The most common adverse events are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. These symptoms occur in approximately 30% to 40% of patients and are typically most pronounced during dose escalation.

GI side effects tend to be more noticeable with Wegovy because the maintenance dose is higher. However, in the STEP UP trial, only 3.3% of patients discontinued due to gastrointestinal adverse events, demonstrating that most patients tolerate semaglutide well even at higher doses.

Semaglutide side effects typically improve within 4 to 8 weeks as the body adjusts. Some patients experience fatigue during the first few weeks, and others report sulfur burps that resolve with dietary adjustments and time.

Both medications carry the same boxed warning about thyroid C-cell tumors, emphasizing the importance of discussing your family history with your provider.

Which Medication Is Right for You?

Ozempic is the appropriate choice if you have a diagnosis of type 2 diabetes and your primary goal is improving blood sugar control. Ozempic also carries FDA approval for reducing cardiovascular risk and slowing kidney disease progression in patients with diabetes. Weight loss occurs as an additional benefit.

Wegovy is the appropriate choice if your primary goal is weight loss and you meet the BMI criteria (30 or greater, or 27 or greater with a weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes). Wegovy delivers a higher dose of semaglutide, optimized specifically for chronic weight management.

Some patients explore compounded semaglutide as an alternative. Green Relief Health offers compounded semaglutide programs and semaglutide with B12 formulations that support weight loss and nutritional needs.

How Semaglutide Compares to Other Weight Loss Medications

Semaglutide is not the only GLP-1 receptor agonist available for weight management. Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss) is a dual GIP/GLP-1 receptor agonist. A 2024 meta-analysis found that tirzepatide produced approximately 4% greater body weight reduction than semaglutide across multiple studies.

What to Expect When Starting Treatment

Both Ozempic and Wegovy begin with a 0.25 mg weekly dose for the first 4 weeks. This titration period allows your body to adjust and minimizes gastrointestinal side effects.

Most patients notice appetite suppression within the first 1 to 2 weeks. Meaningful weight loss typically becomes visible in weeks 4 to 8 as doses increase. Some patients experience a plateau after several months, which providers address by adjusting the dose.

Supporting your treatment with proper nutrition enhances results. B12 supplementation helps maintain energy during caloric reduction.

Frequently Asked Questions